Clinical trials: Kidney Transplant Recipient, open to volunteers
Kidney Transplant Rejection
Treatment of Chronic Active Antibody Mediated Rejection With Tocilizumab
Chronic active antibody mediated rejection (CAMR) is a therapeutic challenge in transplant recipients that does not respond well to conventional treatments for acute antibody mediated rejection (AMR).
- Trial name
- NCT07006532
- Testing
- Tocilizumab
- Where
- Iran
- Volunteers
- 50 people
- Sponsor
- Shahid Beheshti University of Medical Sciences
Liver Transplant Infection, Kidney Transplant Infection
Impact of Culture of Perfusion Fluid on Donor-derived Infection Management and Outcome in Liver and Kidney Transplant
This study aims to evaluate whether microbiological testing of the perfusion fluid used to transport transplanted organs can help predict the development of infections in liver and kidney transplant recipients, including possible…
- Conditions
- Liver Transplant Infection, Kidney Transplant Infection, Liver Transplant, Kidney Transplant
- Trial name
- PREVENT (NCT07651137)
- Where
- Italy
- Volunteers
- 1,400 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Kidney Transplant Recipient, Kidney Transplant; Complications
Vascular Complications After Kidney Transplantation
To determine the incidence of arterial inflow problems and venous outflow problems as causes of impaired renal function and/or treatment-resistant hypertension after kidney transplantation, when all kidney-transplant recipients…
- Conditions
- Kidney Transplant Recipient, Kidney Transplant; Complications, Transplant Renal Artery Stenosis, Renovascular Disease
- Trial name
- DAN-PTRAIII (NCT07531966)
- Testing
- Catheter-based angiography, Measurement of translesional pressure gradients, Intravascular ultrasound (IVUS)
- Where
- 3 sites in Denmark
- Volunteers
- 60 people
- Sponsor
- University of Aarhus
Cytomegalovirus, Organ Transplant
Strategic Help With Immunoglobulin to Enhance Protect Against Late Disease (CMV)
This study is being done to find out if administering CytoGam® after the end of standardly prescribed preventive antiviral treatment can help transplant recipients with a high risk for developing late CMV disease after a liver…
- Conditions
- Cytomegalovirus, Organ Transplant, Kidney Transplant; Complications, Liver Transplant Complications
- Trial name
- SHIELD (NCT06958796)
- Testing
- Cytomegalovirus Immune Globulin Intravenous (Human) monthly for three months
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- Camille N. Kotton, MD
Rejection Chronic Renal
Belumosudil for Abrogation of Interstitial Fibrosis and Tubular Atrophy Following Kidney Transplantation
This is a randomized, double-blind, placebo-controlled trial in de novo kidney transplant patients to determine if the addition of belumosudil (brand name- REZUROCK®) on the background of standard immunosuppression will prevent…
- Trial name
- NCT06751602
- Testing
- Belumosudil 200 mg QD
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- The Methodist Hospital Research Institute
Kidney Transplantation, Cytomegalovirus Infections, EBV Infection
Is Valacyclovir Non-inferior to Valganciclovir as CMV and EBV Prophylaxis in Kidney Transplant Recipients? A Single-Center Prospective Randomized Pilot Study
Opportunistic CMV viremia (primary infection or reactivation) is usually managed by taking prophylactic medication for both adult and pediatric kidney transplant patients.
- Conditions
- Kidney Transplantation, Cytomegalovirus Infections, EBV Infection, Antiviral Prophylaxis
- Trial name
- NCT07294547
- Testing
- Valacyclovir (Valtrex), Valganciclovir (Valcyte)
- Where
- Taiwan
- Volunteers
- 80 people
- Sponsor
- National Taiwan University Hospital
Renal Transplant Failure
The Use of Urinary Dickkopf 3 (u DKK3) as a New Biomarker Which Can Identify Patients at High Risk of Renal Allograft Dysfunction, Earlier That the Current Established Tests.
Kidney function after a renal transplant is monitored closely, particularly in the first year, as the risk of deterioration in graft function is worrying. Graft dysfunction can lead to chronic kidney failure and graft loss.
- Trial name
- NCT07176806
- Where
- United Kingdom
- Volunteers
- 258 people
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust
Kidney Tansplant, Acute Rejection (AR) of Transplanted Kidney
Daratumumab for Late Antibody-Mediated Rejection
The study titled "Daratumumab for Late Antibody-Mediated Rejection in Kidney Transplant Recipients with De Novo Donor-Specific Antibodies" (DARTABMR) is a case-control investigation assessing whether daratumumab is more effective…
- Trial name
- DARTABMR (NCT07081126)
- Testing
- Daratumumab (Subcutaneously), control group
- Where
- Slovakia
- Volunteers
- 20 people
- Sponsor
- University Hospital, Martin
Kidney Transplantation
Digital Application-Based Nursing Intervention
The purpose of this study is to evaluate the effect of a digital application-based nursing intervention on improving health outcomes among kidney transplant recipients.
- Trial name
- NCT07701057
- Testing
- Digital Application-Based Nursing Intervention
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Assiut University
Skin Cancer, Kidney Transplant Recipients
Pilot Trial of Supplemental Vitamin A and Nicotinamide
The goal of this clinical trial is to assess the feasibility and safety of oral nicotinamide (NAM; a derivative of vitamin B3 [niacin]) and vitamin A in a high-risk population of kidney transplant recipients with a history of…
- Trial name
- NCT05702398
- Testing
- Vitamin A, Nicotinamide
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Rhode Island Hospital
CMV Infection, CMV
Letermovir vs Valganciclovir in CMV R+ Kidney Transplant
The purpose of this study is to find out whether letermovir can help prevent cytomegalovirus (CMV) infection in kidney transplant recipients who are CMV seropositive.
- Conditions
- CMV Infection, CMV, CMV Viremia, CMV Disease
- Trial name
- NCT07571135
- Testing
- Letermovir, Valganciclovir CMV Prophylaxis
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Elisabeth Kincaide
Pneumocystis Jirovecii Pneumonia, Kidney Transplantation
Low- vs Standard-Dose TMP-SMX for Prevention of Pneumocystis Pneumonia After Kidney Transplantation
This study is a prospective randomized controlled trial designed to evaluate the efficacy and safety of low-dose versus standard-dose trimethoprim-sulfamethoxazole (TMP-SMX) for the prevention of Pneumocystis jirovecii pneumonia…
- Trial name
- TMP-SMX PJP (NCT07619027)
- Testing
- Trimethoprim-Sulfamethoxazole (TMP-SMX)
- Volunteers
- 1,084 people
- Sponsor
- Anhui Provincial Hospital
Kidney Transplantation
Eight-Treg Study:Trial of Adoptive Immunotherapy With Autologous ex Vivo Expanded Regulatory CD8+ T Cells in Living Donor Kidney Transplant Recipients
The only curative treatment for end-stage renal disease is through kidney transplantation. Solid organ transplants success had been made possible by the development of Immunosuppressive (IS) drugs.
- Trial name
- Eight-Treg (NCT06777719)
- Testing
- Eight Treg
- Where
- France
- Volunteers
- 9 people
- Sponsor
- Nantes University Hospital
Kidney Transplant
Efficacy and Safety of Leymovir Versus Valganciclovir in Prevention of Cytomegalovirus Infection and Cytomegalovirus Disease in Chinese Kidney Transplant Recipients
the existing anti-CMV drugs mainly include valganciclovir, ganciclovir and foscarnet sodium, all of which act on DNA polymerase (pUL54), making them prone to cross resistance.
- Trial name
- CAPS01 (NCT07266467)
- Testing
- Letermovir, Valganciclovir
- Where
- China
- Volunteers
- 290 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Antibody Mediated Rejection After Kidney Transplantation
Safety and Efficacy of the Bispecific T-Cell Engager (BiTE) in Kidney Transplant Recipients With Chronic Active Antibody-Mediated Rejection
This clinical trial aims to determine whether a bispecific T-cell engager (BiTE) targeting BCMA×CD3 effectively treats chronic active antibody-mediated rejection (cAMR) in kidney transplant recipients.
- Trial name
- NCT07689578
- Testing
- BiTE (BCMA x CD3 Bispecific Antibody)
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Turun Song
Epstein-Barr Virus Infections
Evaluation of the Efficacy of a Treatment by One Single Dose of Rituximab (375mg/m2 ) in the Prevention of the Epstein Barr Virus (EBV) Primary Infection and Post-transplant Lymphoproliferative Disorder in Adult EBV Seronegative Patients Who Received an EBV Seropositive Kidney Allograft
Epstein Barr virus infects over 90% of human population and persists during lifetime. After infecting B lymphocytes, EBV remains latent in memory B cells.
- Trial name
- REPLY (NCT04989491)
- Testing
- Rituximab, control group
- Where
- France
- Volunteers
- 120 people
- Sponsor
- University Hospital, Strasbourg, France
Tirzepatide
Tirzepatide (Spartina) in Obese Kidney Transplant Recipients
Post-transplant obesity is a common complication after kidney transplantation, largely attributed to recovery from uremia, increased appetite, sedentary lifestyle, and long-term corticosteroid exposure.
- Trial name
- NCT07423247
- Testing
- Tirzepatide
- Where
- Iran
- Volunteers
- 30 people
- Sponsor
- Shahid Beheshti University of Medical Sciences
Living Donor Kidney Transplantation
TLI, TBI, ATG & Hematopoietic Stem Cell Transplantation and Recipient T Regs Therapy in Living Donor Kidney Transplantation
This study will determine whether a preparatory regimen including total lymphoid irradiation (TLI), total body irradiation (TBI), anti-thymocyte globulin (ATG) and infusion of the donor hematopoietic stem cells when given along…
- Trial name
- NCT03943238
- Testing
- Infusion of Donor Hematopoetic Stem Cells and Recipient Tregs
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- Stanford University
Transplant Recipient (Kidney)
Immune Monitoring-Guided Individualized Tacrolimus Therapy in Renal Transplant Recipients: An Observational Study and PK/PD Modeling
This study aims to resolve the clinical limitation that therapeutic drug monitoring (TDM) alone cannot accurately reflect the net immune status after kidney transplantation.
- Trial name
- NCT07815938
- Testing
- No interventional treatment, only observational data collection without clinical drug adjustment
- Volunteers
- 50 people
- Sponsor
- Zhongnan Hospital
Kidney Transplant Rejection
Autologous Tolerogenic Dendritic Cells (ATDC) for Highly Sensitized Kidney Transplant Recipients
The ATDC-PICI study is a Phase Ib, single-arm, prospective, non-randomized, multicentric trial, to evaluate the safety of ATDC cell product as adjunctive therapy to standard of care (SOC) in highly sensitized kidney transplant…
- Trial name
- ATDC-PICI (NCT06852625)
- Testing
- Autologous Tolerogenic Dendritic Cells
- Where
- 7 sites in Spain
- Volunteers
- 30 people
- Sponsor
- Fundacion Clinic per a la Recerca Biomédica